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Abstract
We have recently synthesized a peptide called Disruptin, which comprised the SVDNPHVC segment of the epi-
dermal growth factor receptor (EGFR) that inhibits binding of heat shock protein 90 (Hsp90) to the EGFR and EGF-
dependent EGFR dimerization to cause EGFR degradation. The effect is specific for EGFR versus other Hsp90
client proteins [Ahsan et al. (2013). Destabilization of the epidermal growth factor receptor (EGFR) by a peptide
that inhibits EGFR binding to heat shock protein 90 and receptor dimerization. J Biol Chem 288, 26879–26886].
Here, we show that Disruptin decreases the clonogenicity of a variety of EGFR-dependent cancer cells in culture
but not of EGFR-independent cancer or noncancerous cells. The selectivity of Disruptin toward EGFR-driven cancer
cells is due to the high level of EGF stimulation of EGFR in EGFR-dependent tumor cells relative to normal cells.
When administered by intraperitoneal injection into nude mice bearing EGFR-driven human tumor xenografts,
Disruptin causes extensive degradation of EGFR in the tumor but not in adjacent host tissue. Disruptin markedly
inhibits the growth of EGFR-driven tumors without producing the major toxicities caused by the Hsp90 inhibitor
geldanamycin or by cisplatin. These findings provide proof of concept for development of a new Disruptin-like
class of antitumor drugs that are directed specifically against EGFR-driven tumors.
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Introduction
Many tumors have oncogenic addiction, and the epidermal growth
factor receptor (EGFR) is among the best established oncogenes [1].
The EGFR is a member of the ErbB family of transmembrane tyrosine
kinases [EGFR/erythroblastic leukemia viral oncogene 1 (ErbB1)/
human epidermal growth factor receptor 1 (HER1), ErbB2/HER2,
ErbB3/HER3, and ErbB4/HER4], which play critical roles in regulat-
ing cell proliferation, differentiation, and migration [2]. The major
clinically approved approaches for treating EGFR-driven tumors
have been the use of the EGFR-specific kinase inhibitor erlotinib or
gefitinib and of the monoclonal anti-EGFR antibodies cetuximab
and panitumumab. Although useful, inhibition of EGFR tyrosine
kinase activity is limited by the development of resistance due to
acquired mutations, such as threonine790methionine (T790M) EGFR
[3,4]. Moreover, there is evidence that EGFR may contribute to the pro-
gression of cancer independent of its kinase activity [5] and that EGFR
degradation is an important mechanism that regulates chemotherapy-
induced cytotoxicity [6–9]. Such findings support the notion that
receptor degradation is more effective in producing cytotoxicity of
EGFR-driven tumors than inhibition of kinase activity alone.
Heat shock protein 90 (Hsp90) is a protein chaperone that
maintains the stability of many oncogenic kinases [10,11], includ-
ing ErbB2 [12,13], wild-type EGFR [14], and erlotinib/gefitinib-
resistant mutant EGFRs [15–17]. The kinase domain of ErbB2 forms
a more stable complex with Hsp90 than with the EGFR, which
undergoes more dynamic cycling with the chaperone and is less
stringently regulated by the Hsp90 chaperone machinery [18]. On
Hsp90 inhibition by geldanamycin (GA), ErbB2 is polyubiquitinated
and rapidly degraded, whereas the EGFR is modestly ubiquitinated
and more slowly degraded [12,13]. This difference in GA sensitivity
is accounted for by an eight–amino acid segment that lies within the
αC-β4 loop region of many protein kinases [19–21]. Swapping
the eight–amino acid segments between the EGFR and ErbB2 yields
the appropriate exchange of dynamic versus stable cycling with Hsp90
and the corresponding change in GA sensitivity [19]. Scrambling the
sequence of the first six amino acids within this segment results in a
mutant EGFR that degrades rapidly [22].
The EGFR is activated by ligand-induced dimerization [23], form-
ing either an asymmetrical homodimer [24] or a heterodimer with
another member of the ErbB2 family. Hsp90 forms a dynamic hetero-
complex with the monomer [22] to restrain signaling by limiting dimer
formation, as was shown for ErbB2 [19]. The eight–amino acid
segment determining GA sensitivity lies in close association with the
EGFR ATP-binding cleft [25] and the receiver dimerization face
[24], and the unstable mutant EGFR with the scrambled sequence does
not undergo EGFR-dependent dimerization and phosphorylation [22].
We postulated that this segment might participate in an inter-
molecular or intramolecular interaction that could be competed with
a peptide containing the eight–amino acid segment (Figure W1).
Accordingly, we synthesized two peptides representing the eight–
amino acid segment of the EGFR, one with the wild-type sequence,
which we call Disruptin, and a second eight–amino acid peptide with
the sequence of the first six amino acids scrambled, which we call
Scram-Peptide [22]. Both peptides were synthesized along with 11
amino acids selected from the human immunodeficiency virus–trans-
activator of transcription (HIV-TAT ) gene to enable cellular uptake
[26]. We found that Disruptin, but not the scrambled peptide, in-
hibits Hsp90 binding to the EGFR and causes slow degradation of
the receptor in EGFR-dependent cancer cell lines in vitro [22]. This
effect is specific for EGFR versus other Hsp90 client proteins. In the
presence of EGF, Disruptin inhibits EGFR dimerization and causes
rapid degradation of the receptor. In contrast to the Hsp90 inhibitor
GA, Disruptin appears to decrease the survival fraction of cancer cells
in culture by a nonapoptotic mechanism.
In this work, we show that Disruptin is active against EGFR-
dependent cancer cells in culture but not against EGFR-independent
cancer or noncancerous cells. Disruptin causes a marked degradation
of EGFR in human head and neck tumor xenografts but not in host
cells outside the tumor periphery. The selectivity of Disruptin toward
EGFR-driven cancer cells is due to the presence of EGF in EGFR-
driven tumor cells and the lack of activation of EGFR in normal
cells. Disruptin markedly inhibits tumor growth without producing
the major tissue toxicities associated with the Hsp90 inhibitor GA or
with cisplatin, an important drug employed against tumors of the
lung and the head and neck. These findings provide proof of concept
for development of a new Disruptin-like class of antitumor drugs
that specifically cause EGFR degradation.
Materials and Methods
Materials
The human head and neck squamous cell carcinoma cell lines
UMSCC1, UMSCC10B, UMSCC17B, and UMSCC74B were
kindly provided by Dr Thomas Carey (University of Michigan,
Ann Arbor, MI). The lung cancer cell lines NCI-H1975 and NCI-
H3255 were provided by Dr J. A. Engelman (Massachusetts General
Hospital, Boston,MA). EGFR-null CHO cells and other cell lines were
purchased from American Type Culture Collection (Manassas, VA).
GA was acquired from Enzo Life Sciences (Farmingdale, NY). EGFR
(sc-03) antibody was acquired from Santa Cruz Biotechnology (Santa
Cruz, CA). Antibodies for glyceraldehyde-3-phosphate dehydrogenase
and cleaved poly(ADP-ribose) polymerase (PARP) were purchased
from Cell Signaling Technology (Danvers, MA), whereas anti-
bodies to detect ErbB2 and ErbB3 were purchased from Neomarkers
(Kalamazoo, MI). Anti-Hsp90 was from BD Pharmingen (San Diego,
CA). Streptavidin and Alexa Fluor 568 and 488 reagents were from
Life Technologies (Grand Island, NY).
Methods
Cell culture and clonogenic survival assay. All cell lines were
grown in RPMI-1640 supplemented with 10% calf serum (Fisher
Scientific, Pittsburgh, PA; Catalog No. SH3008704IR). For all in vitro
experiments, cells were released from flasks using phosphate-buffered
saline (PBS) containing 0.25% trypsin and 0.2 mM EDTA, and cells
were plated onto culture dishes 2 days before any treatment.
Clonogenic assays were performed using a standard technique
described previously [27]. Briefly, 500 cells were plated onto 60-mm
dishes in triplicate, and the next day, cells were treated with Disruptin
or the scrambled peptide, dissolved in distilled water. Eight to 10 days
later, cells were fixed with acetic acid/methanol (1:7, vol/vol), stained
with crystal violet (0.5%, wt/vol), and counted using a stereomicro-
scope. The fraction surviving each treatment was normalized to the
survival of the control cells. Cell survival curves were fitted using the
equation SF = (C 50)
m/[(C 50)
m + Cm], where SF is the surviving
fraction, C is the peptide concentration, C50 is the concentration of
peptide that produces a 50% cell survival, and m is the slope of the
sigmoid curve.
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Immunoblot analysis. Cells were scraped into PBS containing a
sodium orthovanadate and protease inhibitor mixture (Roche Diag-
nostics Co, Indianapolis, IN). Cells were incubated for 15 minutes
on ice in Laemmli buffer [63 mM Tris-HCl, 2% (wt/vol) sodium
dodecyl sulfate, 10% (vol/vol) glycerol, and 0.005% (wt/vol) bromo-
phenol blue] containing 100 mM NaF, 1 mM Na3Vo4, 1 mM
PMSF, and 1 μg/ml aprotinin. After sonication, particulate material
was removed by centrifugation at 13,000 rpm for 15 minutes at 4°C.
The soluble protein fraction was heated to 95°C for 5 minutes, then
applied to a 4% to 12% bis-tris precast gel (Life Technologies) and
Figure 1. Selective effect of Disruptin on EGFR-driven tumor cells. (A) Effect of Disruptin on EGFR and cell survival. The indicated cancer
or noncancerous cells were treated with vehicle (C), 50 nM GA, 10 μM Disruptin (Dis), or 10 μM scrambled peptide (Scr) for 72 hours.
Lysates were prepared and immunoblotted for EGFR, Hsp70, cleaved PARP, and glyceraldehyde-3-phosphate dehydrogenase. Cell
survival was assessed using a colony formation assay. Survival fraction data are means ± SE from the three experiments. *, significantly
different from control at P < .05. (B and C) Effect of EGF stimulation on EGFR degradation in noncancer cells. (B) Het1A or (C) MRC5
cells were treated with vehicle (control), 30 ng/ml EGF, 10 μM Disruptin, or both EGF and Disruptin, and at the indicated times, lysates
were prepared and immunoblotted for EGFR. The blots were scanned, and data are means ± SE for three experiments. **, significantly
different from control at P < .01.
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transferred onto a polyvinylidene fluoride (PVDF) membrane. Mem-
branes were incubated for 1 hour at room temperature in blocking
buffer consisting of 3% BSA and 1% normal goat serum in TBS
[137 mM NaCl, 20 mM Tris-HCl (pH 7.6), and 0.1% (vol/vol)
Tween 20]. Membranes were subsequently incubated overnight at
4°C with 1 μg/ml primary antibody in blocking buffer, washed, and
incubated for 1 hour with HRP-conjugated secondary antibody (Cell
Signaling Technology). After three additional washes in TBS, bound
antibody was detected by Enhanced Chemiluminescence Plus reagent
(GE Healthcare Life Sciences, Piscataway, NJ).
Detection of internalized peptide and immunostaining of tumor
tissue. The UMSCC1 xenografts were cryopreserved in ornithine
carbamoyltransferase (Electron Microscopy Sciences, Hatfield, PA).
Five-micrometer sections were cut from tissues prepared on day 3
after peptide treatment. Sections were fixed in cold methanol for
20 minutes and then were blocked with 1% BSA. The sections were
incubated overnight with anti-EGFR antibody. After washing, the
sections were incubated with anti-rabbit Alexa Fluor 488 (Life Tech-
nologies) and streptavidin-conjugated Alexa Fluor 568 (Life Technol-
ogies). Coverslips were mounted with one drop of ProLong Gold
antifade reagent containing 4,6-diamidino-2-phenylindole (Life
Technologies) to visualize the nuclei. Fluorescence images were
acquired using a DP70 camera fitted on an Olympus IX71 microscope
(Center Valley, PA).
For immunofluorescence analysis of EGFR and Hsp90 expression,
5-μm thick sections were prepared from formalin-fixed, paraffin-
embedded tissue. After slides were deparaffinized in xylene and rehy-
drated using serial ethanol dilutions, antigen site unmasking was
performed by immersing slides in 100 nM citrate buffer for 20 min-
utes at high pressure and temperature inside a pressure cooker. Slides
were then washed in PBS, blocked for 1 hour, and incubated in pri-
mary antibody at 4°C overnight. Slides were then washed again in
PBS, incubated in secondary antibody for 1 hour, rewashed, and pre-
pared with a coverslip after a drop of ProLong Gold antifade reagent
with 4,6-diamidino-2-phenylindole (Life Technologies) was added to
each sample. Fluorescence images were acquired as mentioned above.
For immunohistochemical analysis of CD31 antibody (clone JC70A;
Dako, Carpinteria, CA), slides were incubated with anti-CD31 anti-
body overnight at 4°C (1:50). The EnVision peroxidase detection
kit (Dako) was used to visualize the signal. Slides were counterstained
with hematoxylin and then dehydrated to xylene before the coverslip
was placed.
In vivo tumor growth studies. The in vivo studies were approved
by and run in accordance with the policies of the University Com-
mittee for the Use and Care of Animals. To generate tumor xeno-
grafts, 2 × 106 UMSCC1 or NCI-H1975 cells were transplanted
into the flanks of athymic nude Foxn1nu mice (Harlan Laboratories,
Indianapolis, IN). When the tumors reached a volume of ∼50 mm3
(approximately 5-6 days for NCI-H1975 and 10-12 days for
UMSCC1 cells), the mice were randomized into three groups (one
untreated control and two experimental groups for Disruptin and
scrambled peptide) containing from 15 to 26 tumors, and treat-
ment was initiated. All the agents (except erlotinib; Genentech,
San Francisco, CA) were injected through intraperitoneal (i.p.) route.
Erlotinib was given orally for 5 days.
Tumor volume doubling was determined for each xenograft by
identifying the earliest day on which it was at least twice as large
Figure 2. I.p. administration of Disruptin causes EGFR degradation
in UMSCC1 xenografts. (A) EGFR immunostaining. Mice bearing
UMSCC1 xenograft tumors were injected i.p. with 8 mg/kg scram-
bled peptide or Disruptin. Three days after treatment, tumors were
removed, cryosections were immunostained for EGFR (green),
and the internalized biotin-conjugated peptides (red) were visual-
ized by streptavidin–Alexa Fluor 568 reagent. (B) Effect and selec-
tivity of Disruptin treatment were evaluated by immunoblotting
tumor cell lysates for EGFR and two members of the ErbB family
that are classic Hsp90 client proteins. (C) Differential effect of
Disruptin onEGFR in tumor versus adjacent normal tissue.Oneweek
after two injections, tumors (white arrow) along with adjacent nor-
mal tissue (yellow arrow) were harvested and immunostained for
EGFR (red) and Hsp90 (green). The dotted white line in the upper
panels demarcates the border between tumor and normal tissue
above it.
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as on the first day of treatment. A cubic smoothing spline method,
which provides an estimate of the growth curve from the observed
data [28], was used to obtain the time of tumor doubling. The
Kaplan-Meier method was used to analyze the doubling times
derived from the smoothed growth curves, and the log-rank test
was used for comparisons between any two treatment groups. Results
for continuous variables are presented as means ± SEM, and Stud-
ent’s t test was used to assess the statistical significance of differences.
A significance level threshold of P < .05 was used.
Toxicity analysis and pathologic evaluation. Disruptin was eval-
uated for acute toxicity in immunocompetent 5-week-old C57BL/6
mice (Charles River Laboratories, Wilmington, MA), and the
scrambled peptide was used as control. Cisplatin (University of
Michigan Hospital, Ann Arbor, MI) and GA were used as agents
that have known toxicity profiles as positive control for this exper-
iment. Mice were injected i.p. with 10 or 30 mg/kg Disruptin,
scrambled peptide, GA, or cisplatin. Three days after injection, the
brain, lung, liver, heart, kidney, stomach, small intestine, cecum, colon,
Figure 3. Effect of Disruptin on UMSCC1 xenograft growth. (A) The effect of Disruptin on tumor growth was assessed after a single i.p.
injection of 8 mg/kg. (B) Time to tumor volume doubling was plotted for each treatment condition using the Kaplan-Meier method. (C)
Comparisons between any two treatment groups were analyzed by log-rank tests. ***, significantly different from control at P < .001.
Numbers in parentheses represent the lower and upper limits of doubling time.
Figure 4. Effect of a double dose of Disruptin on UMSCC1 xenograft growth. (A) The effect of Disruptin on tumor growth was assessed
after two 8 mg/kg i.p. injections of Disruptin separated by 3 days. (B) Time to tumor volume doubling was plotted for each treatment
condition using the Kaplan-Meier method. (C) Comparisons between any two treatment groups were analyzed by log-rank tests. ***,
significantly different from control at P < .001.
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ovaries, uterus, bladder, spleen, mesenteric lymph nodes, thymus,
left and right eyes, and sternal bone marrow were processed for
histologic evaluation. The histologic evaluation was performed without
knowledge of the experimental groups by a board-certified veterinary
pathologist at the Pathology Cores for Animal Research in the Unit
for Laboratory Animal Medicine at the University of Michigan.
Results
Selectivity of Disruptin for EGFR-Driven Cells in Culture
We began by assessing the concentration dependence (0-364 μM)
of the effects of Disruptin on UMSCC1 and NCI-H1975 cells by
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumb bromide (MTT)
assay (Figure W2). Both cell lines demonstrated growth inhibition at
or below 10 μM concentration. Therefore, 10 μM concentration of
Disruptin was selected for further experiments. The effect of Disruptin
on clonogenic survival was assessed in several cell lines shown in
Table W1. EGFR-driven cell lines were chosen to represent a spectrum
of EGFR alterations. The three human head and neck cancer cell lines
are driven by wild-type EGFR, and the two lung cancer cell lines
are driven by the erlotinib-resistant T790M and erlotinib-sensitive
leucine858arginine (L858R) EGFR mutants. Disruptin treatment de-
creased the clonogenic survival of all five of the EGFR-dependent cell
lines, and the scrambled peptide had no effect. Disruptin did not affect
the survival of the three EGFR-independent cell lines (Table W1).
To assess the selectivity of Disruptin on EGFR turnover, three
cancer and two noncancer cell lines were treated with Disruptin or
the scrambled peptide, and the cell lysates were immunoblotted for
EGFR. The cells were also treated with GA as a positive control to
demonstrate EGFR degradation when cycling with Hsp90 is inhib-
ited. As illustrated in Figure 1, treatment with GA produced EGFR
degradation and decreased clonogenic survival in all five cell lines.
GA kills cells through an apoptotic mechanism [29], and GA
induced PARP cleavage (an indicator of apoptosis) in all five cell
lines, whereas Disruptin did not (Figure 1A). As we have previously
reported for the UMSCC1 and NCI-H1975 cell lines [22], Disrup-
tin caused EGFR degradation and decreased clonogenic survival in
UMSCC10B and UMSCC17B cells, which are driven by over-
expression of wild-type EGFR. In contrast, in SK-BR-3 breast cancer
cells, which are driven by amplification of ErbB2/HER2 [30] and are
not capable of inducing EGFR dimerization even in the presence of
EGF [31], Disruptin did not degrade endogenous EGFR or decrease
the survival fraction (Figure 1). Het1A cells are derived from human
esophageal autopsy tissue by transfection with pRSV-T, and the
MRC5 cell line was derived from normal human fetal lung tissue.
Disruptin affected neither EGFR level nor clonogenic survival in
these noncancerous cell lines (Figure 1A).
When we observed that Disruptin induced EGFR degradation
only in the EGFR-driven tumor cells rather than the normal cells,
we hypothesized that the well-established production of EGF by the
tumor cells played a key role [32,33]. To test this hypothesis, EGFR
was stimulated by EGF treatment in noncancer cells that were also
treated with Disruptin. The effect on EGFR levels was determined over
time (Figure 1, B and C ). Disruptin treatment caused rapid loss of
EGFR in the EGF-treated noncancer cells similar to that seen in
EGFR-driven cancer cells. Taken together, the data of Table W1
and Figure 1 suggest that Disruptin is selective against cells that are
capable of inducing EGFR dimerization in the presence of EGF.
Disruptin Effect on EGFR in Tumor Xenografts
Disruptin or scrambled peptide were injected i.p. into nude mice
bearing established UMSCC1 xenografts, and after 3 days, cryo-
sections of tumor tissue were prepared and immunostained for
EGFR (green) and the biotin-containing peptide (red). As shown
in Figure 2A, the biotin signal from both peptides is present in the
tumor tissue, and there is a marked decrease in immunostained
EGFR in the Disruptin-treated tumor versus tumor treated with
the scrambled peptide. Immunoblot analysis of tumor tissue lysate
shows a marked reduction of EGFR level that is not seen with the
classic Hsp90 client proteins ErbB2 and ErbB3 (Figure 2B).
As we found with cells in culture (Figure 1), the EGFR in the
EGFR-driven tumor tissue is markedly reduced by Disruptin treat-
ment, whereas the EGFR in normal tissue is not. In the experi-
ment shown in Figure 2C , slices containing both UMSCC1 tumor
and adjacent normal tissue were prepared 1 week after two injec-
tions of Disruptin. The EGFR immunostaining (red in top row of
panels) in Disruptin-treated tumor (below the white dotted line) is
markedly reduced compared to tumor tissue from control mice or
mice treated with the scrambled peptide. In contrast, EGFR immuno-
staining in the normal tissue (above the dotted white line) has the
Figure 5. Effect of Disruptin treatment on xenograft tumor histol-
ogy and vascularization. (A) Histology. Mice bearing UMSCC1 or
NCI-H1975 xenografts were treated with saline, scrambled pep-
tide, or Disruptin. Tumors were harvested 1 week later and stained
with hematoxylin and eosin. A representative field from each group
is included. (B) Tumor slices were stained with antibody against
CD31. **P < .01 and ***P < .001. Original magnification, ×200.
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same intensity in Disruptin-treated and control samples. A number of
reports published during the 1990s noted that a variety of Hsps were
expressed at higher levels in various cancers than in normal tissues,
probably as a stress response to conditions of hypoxia and low pH
generated in tumors [34]. The overexpression of Hsp90 in tumor versus
normal tissue is clearly apparent in Figure 2C (middle row of panels).
Effect of Disruptin on Xenograft Growth
The effect of a single 8 mg/kg injection of Disruptin on UMSCC1
tumor growth is presented in Figure 3. Disruptin slowed the increase
in relative tumor volume (Figure 3A) by increasing the median tumor
doubling time from 4.5 to 16 days (Figure 3, B and C ). A single
injection of 8 mg/kg Disruptin is approximately equally effective to
50 mg/kg cetuximab or five oral doses of 100 mg/kg erlotinib against
UMSCC1 xenografts (Table W2). When two 8 mg/kg injections are
given 3 days apart, more profound effects on tumor growth and
doubling time are obtained (Figure 4). A similar analysis of the effect
of Disruptin on NCI-H1975 human lung tumor xenografts is shown
in Figure W3. These tumors grew more rapidly than UMSCC1 xeno-
grafts, but the median tumor doubling time with Disruptin is never-
theless more than three-fold compared to either Scram-Peptide or
1 week of erlotinib treatment.
To assess the effect of Disruptin on tumor histology, UMSCC1
and NCI-H1975 tumor slices were stained with hematoxylin and
eosin (Figure 5A). The control and scrambled peptide samples had
homogenous tumor architecture; whereas the Disruptin-treated
UMSCC1 tumors had decreased tumor mass and more connective
tissue, the Disruptin-treated NC1-H1975 tumors had decreased
tumor cells with more necrosis. Xenograft slices were also stained
with antibody against the endothelial cell adhesion molecule CD31
[platelet endothelial cell adhesion molecule (PECAM-1)] glycoprotein
to assess tumor cell vascularization, which is markedly less in tumor
samples from animals treated with Disruptin versus the scrambled
peptide (Figure 5B).
Histopathologic Alterations in Mice Treated with
GA, Cisplatin, or Disruptin
The effects of Disruptin on selected tissues are compared with
those of GA and cisplatin in Figure 6. GA-treated animals developed
hepatic necrosis and acute cataract formation (arrows indicate glob-
ular degeneration of lens fibers). Cisplatin-induced histologic changes
Figure 6. Disruptin toxicity screen in mice. Female C57BL/6 mice were given i.p. injections of 10 mg/kg GA, 10 mg/kg cisplatin, 30 mg/kg
scrambled peptide, or 30 mg/kg Disruptin. Three days later, histologic evaluation was carried out on brain, lung, liver, heart, kidney,
stomach, small intestine, cecum, colon, ovaries, uterus, bladder, spleen mesenteric lymph nodes, thymus, eyes, and sternal bone
marrow. Histologic evaluation was performed without knowledge of the experimental group by a certified pathologist at the Unit for
Laboratory Animal Medicine facility at the University of Michigan. Original magnification, ×600 (for lens and bone marrow) and ×400 (for
other tissues).
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were consistent with its activity against rapidly proliferating cells
as evidenced by villus damage in the intestine (marked by arrows),
depletion of hematopoietic elements in bone marrow (asterisk), and
ovarian follicular degeneration (arrows indicate degenerating fol-
licles). Neither Disruptin nor the scrambled peptide produced
acute (3-day) histopathologic changes, and complete blood counts
and liver cytosolic enzymes did not differ from control mice (data
not shown).
Discussion
In this study, we show that Disruptin, a 19–amino acid peptide
designed to prevent Hsp90 binding to the EGFR monomer and
EGFR dimerization, selectively promotes EGFR turnover and de-
creased survival in EGFR-dependent tumor cell lines versus EGFR-
independent cancer cells and noncancerous cells. Disruptin also
selectively increases the turnover of EGFR in an EGFR-driven tumor
xenograft versus EGFR in adjacent normal tissue (Figure 3). To explain
this extraordinary degree of selectivity, we must consider both how
Disruptin works and the state of the EGFR in EGFR-dependent
tumor cells.
As outlined in the model of Figure 7, in the absence of EGF, the
EGFR is primarily present as the nonphosphorylated monomer,
which is the form that cycles into heterocomplex with Hsp90 [22].
Hsp90 cycling with the monomer stabilizes the EGFR, and inhibi-
tion of Hsp90 binding with Disruptin causes very slow EGFR deg-
radation [22]. Thus, in the absence of EGF, Disruptin is competing
with the stabilizing effect of the Hsp90/Hsp70-based chaperone
machinery in cycling Hsp90 with an otherwise unstable monomer.
Hsp90 and Hsp70 are very abundant proteins, and, at the concen-
trations used in this work, Disruptin partly inhibits but does not
block cycling with Hsp90. On EGF binding, the EGFR undergoes
a conformational change in the region of the αC helix [35] adja-
cent to the SVDNPHVC segment comprising Disruptin such that
the receptor can no longer cycle with Hsp90. In the presence of
EGF, it is likely that Disruptin specifically affects the EGFR by
competing with the eight–amino acid segment at the dimerization
interface, which is also where Hsp90 binds. This would account
for both Disruptin inhibition of Hsp90 binding to the EGFR mono-
mer and inhibition of EGF-stimulated EGFR dimerization. Dis-
ruptin inhibits EGFR dimerization, but the EGF-bound EGFR
monomer cannot be stabilized by Hsp90. Thus, in the presence
of EGF, the EGFR is degraded very rapidly when Disruptin is also
present [22].
In normal cells in the absence of EGF stimulation, the EGFR is
predominantly present as the unphosphorylated monomer, whereas
in EGFR-driven tumor cells, the receptor is activated and highly
phosphorylated. This difference in EGFR phosphorylation has also
been noted in paired tumor and normal tissue samples [36,37].
The EGFR-driven tumor cells produce EGF, which stimulates
EGFR dimerization, whereas the non–EGFR-driven tumor cells,
noncancer cells, and tumor-adjacent normal tissue are not exposed to
high levels of EGF and remain relatively unaffected versus EGFR-driven
cells in culture and in tumor xenografts. As we noted in our previous
mechanistic study, when it comes to promoting EGFR turnover, it
seems that Disruptin is more effective at inhibiting EGFR dimerization
than cycling of the ligand-free EGFR with Hsp90.
The selectivity of Disruptin for EGFR-driven tumors is reflected
in the lack of acute toxicity, as seen in Figure 6. As opposed to GA,
Disruptin does not cause a change in the Hsp70 levels (Figure 1),
demonstrating that the peptide is not an inhibitor of Hsp90 in
general. This also explains the lack of acute toxicity and stands in
contrast to the toxicity of the general Hsp90 inhibitor GA, which
promotes the turnover of a wide variety of client proteins. We used
GA as a “proof of principle” Hsp90 inhibitor to demonstrate that we
could detect toxicity produced by Hsp90 inhibition, and we recog-
nize that newer Hsp90 inhibitors such as ganetespib may be less toxic
than first-generation agents [38]. However, all Hsp90 inhibitors, by
their nature, affect dozens if not hundreds of normal as well as abnor-
mal signaling molecules, which have produced unwanted toxicity
and have hampered clinical development.
We and others have found that EGFR degradation increases
tumor cell–specific cytotoxicity of chemotherapy and radiotherapy
beyond that of EGFR inhibition alone [6,39,40]. These studies
support the notion that down-regulation of EGFR, not just inhi-
bition of EGFR tyrosine kinase activity, is an important target in
cancer therapy [41,42]. As we have seen here, GA promotes EGFR
degradation in both cancer cells and cells of noncancer origin, and
GA and its analog 17AAG have been shown to significantly enhance
both chemosensitivity and radiosensitivity [43,44]. However, as
noted above, these Hsp90 inhibitors have proven to be toxic in
clinical trials [45,46]. Our preliminary observations suggest that
Disruptin enhances chemosensitivity of EGFR-driven tumor cells
in culture, and it might prove useful in a single-injection or two-
injection (as in Figure 4) protocol at increasing tumor cell–specific
cytotoxicity of chemotherapy and radiotherapy with less toxicity
than the Hsp90 inhibitors.
Figure 7. Disruptin interaction with EGFR in presence or absence
of EGF. In the absence of EGF, EGFR cycles with Hsp90. Disruptin
inhibits EGFR cycling with Hsp90, but due to the abundance of the
Hsp90 chaperone machinery in cells, EGFR cycling with Hsp90 is
minimally affected, permitting only slow degradation of EGFR. In
contrast, in the presence of EGF, EGFR forms a dimer, and the EGF-
bound EGFR cannot bind with and be stabilized by Hsp90. Disruptin
inhibits EGFR dimerization, leaving EGF-bound EGFR in the unstable
monomeric form and resulting in rapid EGFR degradation.
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We have shown here that Disruptin is active against an erlotinib-
resistant lung cancer cell line, and we think that it should be effective
against EGFR-driven cancers, including those that are driven by
EGFR class III variant and are resistant to other anticancer drugs.
Despite the fact that Disruptin is a peptide and there is a general
aversion to peptide drugs by pharmaceutical manufacturers, its
specificity and potential lack of toxicity might make it attractive
as a short-term agent to provide synergistic enhancement of other
therapies directed against EGFR-driven tumors. Recently, small
peptides have shown efficacy in blocking the interaction of Bcl-XL
with Bcl2-associated X protein (Bax) [47], p53 with mouse double
minute 2 homolog (MDM2) [48], and Sal like 4 (SALL4) with its
epigenetic histone deacetylase (HDAC) [nucleosome remodeling
deacetylase (NuRD)] complex [49,50] in preclinical cancer therapy
models. This suggests that the use of peptides, like Disruptin, that
block protein-protein interactions in the cell may move into the
clinic as a new approach to cancer treatment.
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Figure W1. SVDNPHVC loop in X-ray structure of EGFR [protein data
bank (PDB) 1M14].
Figure W2. Efficacy and specificity of Disruptin. Dose-response
relationship of Disruptin on cell growth was assessed at 24 hours
using MTT assay against UMSCC1 and NCI-H1975 cell lines.
Table W1. Effects of Disruptin on Clonogenic Survival of EGFR-Dependent or EGFR-Independent Cancer Cells.
EGFR-Dependent EGFR-Independent
Head and Neck Lung Breast Colon Ovarian
Cell Line UMSCC1 UMSCC10B UMSCC74B NCI-H1975 NCI-H3255 SK-BR-3 SW620 CHO
EGFR WT WT WT T790M L858R WT Null Null
Scram-Peptide 1.02 ± 0.04 0.96 ± 0.04 1.08 ± 0.08 0.99 ± 0.19 1.00 ± 0.07 1.14 ± 0.10 1.03 ± 0.06 1.12 ± 0.14
Disruptin 0.76 ± 0.02 0.63 ± 0.06 0.76 ± 0.1 0.48 ± 0.04 0.71 ± 0.05 0.99 ± 0.12 1.05 ± 0.08 0.98 ± 0.02
Five EGFR-dependent and three EGFR-independent cell lines were treated with 10 μg/ml Disruptin or scrambled peptide, and cell survival was assessed using a colony formation assay. Results are
expressed as a fraction of vehicle control (means ±SEM) of three experiments. WT, wild_type EGFR; T790M and L858R are erlotinib-resistant and erlotinib-sensitive EGFR mutants, respectively; Null,
do not express EGFR protein; SK-BR-3 contains WT EGFR but is driven by ErbB2/HER2.
Table W2. Relative Effectiveness of Disruptin.
Median Tumor Doubling Time (Days) Lower Limit Upper Limit P Value
Control 4 3 9 -
Erlotinib (100 mg/kg, p.o., Mon-Fri) 15 2 - 0.065
Cetuximab (50 mg/kg, i.p. one injection) 21 5 - 0.007
Disruptin (8 mg/kg, i.p. one injection) 16 4 - 0.034
Nude mice bearing UMSCC1 xenografts were treated with the indicated therapy. Whereas cetuximab or disruptin was injected once, erlotinib was given on five conjunctive days. The tumor growth was
recorded every other day, and the median tumor volume doubling time was calculated as described in Methods section. The effect of each treatment was compared to untreated control.
Figure W3. Effect of a double dose of Disruptin on NCI-H1975 xenograft growth. (A) The effect of Disruptin on tumor growth was
assessed after two 8 mg/kg i.p. injections of Disruptin separated by 3 days. One set of animals was treated with erlotinib (100 mg/kg,
per oral, for 1 week). (B) Time to tumor volume doubling. (C) Comparison between treatment groups. ***, significantly different from
control at P < .001.
